Literature DB >> 32606118

False-positive paracetamol levels in a patient with hyperbilirubinaemia: clinical perspectives.

Joel James1, Madelena Stauss2, Arvind Ponnusamy2, Martin Myers2.   

Abstract

​Serum concentrations of paracetamol are measured to investigate the cause of acute hepatitis, monitor the clearance of paracetamol from the body and to determine if supratherapeutic levels warrant treatment with N-acetylcysteine (NAC). ​A 49-year-old man treated for ischaemic colitis developed worsening renal and liver function tests. As part of the investigation of hepatorenal failure, paracetamol levels were requested, which were elevated at 14 mg/L (normal <4 mg/L) resulting in treatment with NAC. Despite treatment, levels of paracetamol remained elevated and the link between hyperbilirubinemia and false-positive paracetamol levels was identified. ​Bilirubin and its by-products have intense absorbance in the ultraviolet and visible regions of the electromagnetic spectrum, causing interference in the enzymatic colorimetric assay most commonly used to measure paracetamol concentration, resulting in false-positive paracetamol levels. Laboratories correct for this interference above a predetermined bilirubin concentration, termed the Icteric Index; however, in our case this interference occurred at a lower level of hyperbilirubinaemia than previously identified as significant. This interaction was found to be more significant at lower bilirubin levels when low or no paracetamol levels were present in the serum, resulting in a change to laboratory practice and development of a 'Sliding Scale' approach to analysis. ​Concurrent bilirubin or Icteric Index measurement is recommended for all laboratories that use the enzymatic colorimetric assay for paracetamol measurement. Lower Icteric Index or bilirubin thresholds are required when low or no paracetamol levels are present in the serum to prevent false-positive paracetamol results. We describe a new 'Sliding Scale' approach to analysis, and highlight an important interaction for clinicians to be aware of. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  drugs: gastrointestinal system; hepatitis other; nonalcoholic steatosis

Mesh:

Substances:

Year:  2020        PMID: 32606118      PMCID: PMC7328752          DOI: 10.1136/bcr-2020-234702

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Persistently increased acetaminophen concentrations in a patient with acute liver failure.

Authors:  Bonnie Mei-wah Fong; Tak Shing Siu; Sidney Tam
Journal:  Clin Chem       Date:  2011-01       Impact factor: 8.327

Review 2.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

3.  The Natural History of Severe Acute Liver Injury.

Authors:  David G Koch; J L Speiser; V Durkalski; R J Fontana; T Davern; B McGuire; R T Stravitz; A M Larson; I Liou; O Fix; M L Schilsky; T McCashland; J E Hay; N Murray; O S Shaikh; D Ganger; A Zaman; S B Han; R T Chung; R S Brown; S Munoz; K R Reddy; L Rossaro; R Satyanarayana; A J Hanje; J Olson; R M Subramanian; C Karvellas; B Hameed; A H Sherker; W M Lee; A Reuben
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

4.  Effect of hemolysis, icterus, and lipemia on three acetaminophen assays: Potential medical consequences of false positive results.

Authors:  Y Victoria Zhang; Shu-Ling Fan; Mark D Kellogg
Journal:  Clin Chim Acta       Date:  2018-10-11       Impact factor: 3.786

5.  False positive acetaminophen levels associated with hyperbilirubinemia.

Authors:  Michael C Beuhler; Steven C Curry
Journal:  Clin Toxicol (Phila)       Date:  2005       Impact factor: 4.467

6.  FibroScan® and transient elastography.

Authors:  William Kemp; Stuart Roberts
Journal:  Aust Fam Physician       Date:  2013-07

7.  False positive acetaminophen concentrations in patients with liver injury.

Authors:  Julie Polson; Frank H Wians; Paul Orsulak; Dwain Fuller; Natalie G Murray; Jonathan M Koff; Adil I Khan; Jody A Balko; Linda S Hynan; William M Lee
Journal:  Clin Chim Acta       Date:  2008-01-26       Impact factor: 3.786

8.  Acute Liver Failure: Diagnosis and Management.

Authors:  Carmi S Punzalan; Curtis T Barry
Journal:  J Intensive Care Med       Date:  2016-07-09       Impact factor: 3.510

9.  Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose.

Authors:  Janice M Pettie; Thomas M Caparrotta; Robert W Hunter; Emma E Morrison; David M Wood; Paul I Dargan; Ruben H Thanacoody; Simon H L Thomas; Muhammad E M O Elamin; Ben Francis; David J Webb; Euan A Sandilands; Michael Eddleston; James W Dear
Journal:  EClinicalMedicine       Date:  2019-05-02

10.  Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial.

Authors:  D Nicholas Bateman; James W Dear; H K Ruben Thanacoody; Simon H L Thomas; Michael Eddleston; Euan A Sandilands; Judy Coyle; Jamie G Cooper; Aryelly Rodriguez; Isabella Butcher; Steff C Lewis; A D Bastiaan Vliegenthart; Aravindan Veiraiah; David J Webb; Alasdair Gray
Journal:  Lancet       Date:  2013-11-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.